文献速递类风湿关节炎其他结缔组织病

靶向成纤维细胞治疗免疫介导炎性疾病:治愈的细胞学基础?

Targeting fibroblasts in immune mediated inflammatory diseases: a cellular basis for cure?
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该综述指出,单细胞技术揭示了成纤维细胞在健康与免疫介导炎性疾病(IMID)中的高度异质性,其功能涵盖结构支撑、组织身份、基质记忆、免疫调节与纤维化。在RA中成纤维细胞参与滑膜炎症及骨软骨损伤,在IBD中参与上皮屏障丧失、肠道炎症及克罗恩病狭窄与瘘管形成,并与RA和IBD生物制剂无应答相关。靶向致病性成纤维细胞(如CAR T细胞疗法)可能将基质重置为健康状态,为治愈这些疾病带来希望。

要点

  • 成纤维细胞异质性与IMID中结构支撑、免疫调节和纤维化等功能多样性相关。
  • RA成纤维细胞参与滑膜炎症及骨软骨损伤,IBD中参与屏障丧失和狭窄瘘管。
  • 靶向致病性成纤维细胞(如CAR T细胞)可能重置基质为健康状态。

核心结论

  • 靶向致病性成纤维细胞群体可能将基质重置为健康状态,为IMID治愈带来希望。

研究设计与样本

  • 综述,基于单细胞技术进展讨论成纤维细胞异质性及其在IMID中的作用。

主要发现

  • 成纤维细胞异质性与结构支撑、组织身份、基质记忆、免疫调节和纤维化等功能相关。
  • RA中成纤维细胞参与滑膜炎症及骨和软骨损伤。
  • IBD中成纤维细胞参与上皮屏障丧失、肠道炎症及克罗恩病肠道狭窄和瘘管形成。
  • 成纤维细胞与RA和IBD对当前生物制剂治疗无应答相关。

关键数值与推荐

  • 靶向致病性成纤维细胞的新治疗方式如嵌合抗原受体(CAR)T细胞疗法可能重置基质为健康状态。

临床怎么用

  • 靶向致病性成纤维细胞(如CAR T细胞疗法)可能成为IMID治疗新策略,需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibroblasts constitute a major component of our stroma, the supportive bedding in which our tissues reside. The introduction of advanced single-cell technologies has greatly enhanced our appreciation of fibroblast heterogeneity in health and immune-mediated inflammatory diseases (IMIDs). This heterogeneity correlates with their diverse functions, including providing architectural support, tissue identity, 'stromal memory', and regulating immune responses and fibrosis. In RA, fibroblasts contribute to both synovial inflammation and bone and cartilage damage, and in IBD to loss of the epithelial barrier, intestinal inflammation, and the development of intestinal strictures and fistulae in Crohn's disease. Fibroblasts have also been associated with non-response to current biologic therapies in RA and IBD. Targeting pathogenic fibroblast populations using new therapeutic modalities such as Chimeric Antigen Receptor (CAR) T-cell therapies may 'reset' the stroma back to health and give hope for cure in these debilitating IMIDs.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Xenophontos M, Progatzky F, Buckley CD, et al. Targeting fibroblasts in immune mediated inflammatory diseases: a cellular basis for cure? Rheumatology (Oxford). 2026. PMID: 42118595. doi:10.1093/rheumatology/keag249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。